Suven Life Sciences profitability ratios
Per cent unless marked ×
| Tap a line for its trend | Last 12Mto Jun 2026 | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
Returns | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |||||
|---|---|---|---|---|---|---|
| −78.8% | −78.8% | −84.6% | −32.6% | −50.2% | ||
| −72.8% | −72.8% | −76.5% | −31.2% | −47.6% | ||
| −82.3% | −82.3% | −89.6% | −41.4% | −55.5% | ||
| −63.9% | −49.8% | −236.1% | −74.4% | −45.4% | ||
Margins | ||||||
| −4,155.5% | −3,998.8% | −2,490.7% | −1,094.7% | −929.8% | ||
| −4,077.7% | −4,077.7% | −2,578.1% | −1,150.3% | −978.1% | ||
| — | −25,827.2% | 736.3% | 112.6% | — | ||
| −3,998.7% | −3,884.1% | −2,415.1% | −907.2% | −873.5% | ||
| −3,998.7% | −3,884.1% | −2,415.1% | −898.6% | −873.5% | ||
| −4,313.2% | −4,313.2% | −2,875.4% | −727.3% | −1,557.1% | ||
Additional | ||||||
| 0.0% | 0.0% | 0.0% | 0.9% | 0.0% | ||
| −78.8% | −78.8% | −84.6% | −32.6% | −50.2% | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.